Bot Chart, page-456

Just some stuff with no relevance whatsoever, make it what you like:

a)- Psoriasis trial was registered RETROSPECTIVELY early November.
b)- Trial was updated as 'ACTIVE, NOT RECRUITING' on the 12th of February.
c)- On the very same day Dr Michael Thurn - the person in charge of this trial for BOTANIX - was promoted EXECUTIVE DIRECTOR.
d)- From a small study - NOT A CLINICAL TRIAL - presented as part of a patent claim to cure psoriasis with some cannabinoids for an OTC cream:

[0068] Treatment by 3% CBG/CBD oil treatment showed no improvement on the lesions. The 15% CBG/CBD oil treatment showed 16% improvement on Subject 1 and 33% improvement on Subject 2 with psoriasis vulgaris. The improvement was intra-specimen, where the subjects' other lesions served as their own controls.
[0072] The results from this study indicate a possible Th1/Th2 rebalancing mechanism. Despite the fact that only two concentrations have been used, there seems to be a clear dose-response effect, whereby higher doses (15% CBD/CBG oil) are effective where lower doses (3% CBD/CBG oil) do not show any effect. Factors influencing the dose effect might be a limited sufficient skin penetration, since skin penetration of cannabinoids may be poor.

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=AND&d=PG01&s1=%22AXIM+BIOTECHNOLOGIES%22&OS=%22AXIM+BIOTECHNOLOGIES%22&RS=%22AXIM+BIOTECHNOLOGIES%22